EU Pharmaceutical Laws: The Complete Framework

The foundational law governing medicinal products for human use in the EU. It sets out the rules for marketing authorisation, manufacture, wholesale distribution, advertising, and pharmacovigilance through national and decentralised procedures. Adopted in 2001, it consolidated and replaced earlier directives dating back to 1965.

Establishes the European Medicines Agency (EMA) and the centralised marketing authorisation procedure. A single application to EMA results in a single authorisation valid across all EU/EEA Member States. Mandatory for biotech products, orphan medicines, and treatments for cancer, HIV/AIDS, neurodegenerative diseases, diabetes, autoimmune and viral diseases.

Biotechnology products, orphan medicines, HIV/AIDS, cancer, neurodegenerative diseases, diabetes, autoimmune diseases, viral diseases, and advanced therapy medicinal products (gene therapy, somatic cell therapy, tissue engineering). Assessment time: 210 active days.

The EU database of suspected adverse drug reactions, managed by EMA. Marketing authorisation holders must report all suspected serious reactions within 15 days. Key tools include Periodic Safety Update Reports (PSURs), Risk Management Plans (RMPs), and the black triangle symbol for medicines under additional monitoring.

Replaced the Clinical Trials Directive 2001/20/EC. Introduces the Clinical Trials Information System (CTIS): a single EU portal for all trial applications. One application can cover multiple Member States, with coordinated assessment led by a Reporting Member State. Trial results must be published within 12 months of study completion. Simplified rules apply to low-intervention clinical trials.

For diseases affecting not more than 5 in 10,000 people in the EU. EMA's Committee for Orphan Medicinal Products (COMP) grants orphan designation. Incentives include 10 years of market exclusivity, protocol assistance, and fee reductions. Under the 2023 reform, breakthrough orphans will receive up to 11 years.

Requires Paediatric Investigation Plans (PIPs) for all new medicines, assessed by EMA's Paediatric Committee (PDCO). Completing an agreed PIP grants a 6-month SPC extension. Waivers available when a disease does not occur in children or the product would be unsafe.

Covers gene therapy, somatic cell therapy, and tissue-engineered products. Centralised authorisation is mandatory. EMA's Committee for Advanced Therapies (CAT) provides the scientific assessment. These cutting-edge therapies are transforming treatment for rare genetic conditions and cancers.

Simplified registration procedure for traditional herbal medicines with at least 30 years of documented use (including 15 years in the EU). EMA's Herbal Medicinal Products Committee (HMPC) prepares monographs establishing safety and efficacy profiles.

Mandatory safety features on packaging: a unique identifier (2D barcode) and an anti-tampering device, verified at dispensing through the European Medicines Verification System (EMVS). Strengthened supply chain controls cover importers, brokers, and API manufacturers. A common EU logo identifies legal online pharmacies.

On 26 April 2023, the Commission proposed replacing both the Directive (2001/83/EC) and the Regulation (726/2004) with a modernised framework. After four trilogues, negotiators reached a provisional agreement on 11 December 2025. The reform addresses innovation incentives, supply chain resilience, antimicrobial resistance, and patient access.

For the first time in EU pharmaceutical law, the 2026 reform introduces regulatory sandboxes as a formal legislative tool. The European Commission, at the suggestion of the EMA, may establish a sandbox where a medicinal product cannot be developed and authorised under standard regulatory requirements due to its inherent scientific or technical characteristics.

Areas envisaged: personalised medicines, advanced therapy medicinal products (ATMPs), products incorporating artificial intelligence (AI) or digital health tools, and innovative antimicrobials such as phage therapy.

How it works: A controlled, supervised environment where targeted adaptations to current regulatory requirements are permitted. Lessons learned are converted into permanent regulatory rules that reflect scientific progress.

Interplay with AI Act: Companies developing AI-enabled medicinal products must navigate two separate sandbox frameworks: the pharma sandbox under the new regulation, and the AI Act sandbox regime (as strengthened by the Digital Omnibus proposal). These are distinct legal mechanisms with no formal cross-reference between them.

Pharmaceutical compounding refers to the preparation of customised medicines by pharmacies for individual patients. The 2026 Pharma Package clarifies the regulatory boundary between pharmacy compounding (which is exempt from marketing authorisation requirements under Article 3 of Directive 2001/83/EC) and industrial manufacturing.

Key clarifications in the reform:

• Compounding remains under national competence but must comply with Good Pharmacy Practice (GPP)
• Industrial-scale "compounding" that is not for a specific named patient triggers full GMP and marketing authorisation requirements
• The Falsified Medicines Directive (Dir 2011/62/EU) serialisation requirements apply to compounded products only when they enter the supply chain
• The reform does not harmonise compounding rules across Member States, leaving significant national variation (especially between common law and civil law jurisdictions)

Directive (EU) 2024/3019 (CELEX: 32024L3019), adopted 27 November 2024. This recast of the 1991 Urban Waste Water Treatment Directive is the most significant upgrade to EU water treatment rules in 33 years.

Why it matters for pharma:

• Extended Producer Responsibility (EPR): Pharmaceutical and cosmetic producers must finance quaternary treatment (advanced removal of micropollutants) at waste water treatment plants. This is a direct "polluter pays" mechanism: the industry that places micropollutants on the market pays for their removal
• Quaternary treatment: 80% removal of micropollutants (pharmaceuticals, PFAS) required for plants serving 150,000+ population equivalents by 2033, and 10,000+ p.e. by 2039
• EPR cost share: At least 80% of quaternary treatment costs borne by pharmaceutical and cosmetics producers, proportional to their micropollutant load
• Source: EPRS Briefing PE 740.240

Per- and polyfluoroalkyl substances (PFAS) are synthetic chemicals used in pharmaceutical manufacturing (coatings, packaging, equipment). The EU is pursuing the world's most comprehensive PFAS regulatory approach.

Cost of inaction: EUR 440 billion cumulative by 2050. EUR 1 trillion+ in water treatment costs without action. Sources: EC study (January 2026), DG ENV

Regulation (EC) 1907/2006 (REACH) is the EU's main chemicals legislation, enforced by ECHA in Helsinki. DG ENV overview.

Why it matters for pharma:

• Active ingredients: Pharmaceutical active substances are exempt from REACH registration when used in medicinal products (Article 2(5)(a)), but not when used as intermediates or in non-medicinal applications
• Excipients and process chemicals: All non-active chemical substances used in pharmaceutical manufacturing (solvents, excipients, cleaning agents) must be REACH-registered if produced/imported above 1 tonne/year
• SVHC authorisation: If a substance used in pharma manufacturing is added to the Authorisation List (Annex XIV), manufacturers must obtain authorisation for continued use or find substitutes
• REACH targeted revision (2023/0234(COD)): Proposes "One Substance, One Assessment" (OSOA) to streamline hazard assessment across ECHA, EFSA, EMA, and EEA. This directly impacts how pharma substances are evaluated
• Critical Medicines Act connection: The proposed CMA may create exemptions or fast-track procedures for substances essential to critical medicine manufacturing

Hospital and public health system pharmaceutical purchases are governed by the EU public procurement framework:

Key issues for pharma procurement: Joint procurement mechanisms (as used during COVID-19 for vaccines), Most Economically Advantageous Tender (MEAT) criteria allowing quality/innovation weighting over lowest price, and the International Procurement Instrument (Regulation 2022/1031) which can restrict third-country bidders in strategic sectors.

EU trade agreements directly affect pharmaceutical market access, IP protection, and regulatory cooperation:

The EU and the US are the world's two largest pharmaceutical markets. Their relationship is characterised by deep interdependency: European companies develop and manufacture globally, while the US market provides the highest prices and fastest regulatory approvals (FDA).

Key dynamics (2026):

• Tariff risk: US tariff policy under Trump II creates uncertainty for EU pharmaceutical exports. Pharma has historically been exempt from tariff disputes, but the current administration has signalled willingness to include it
• Regulatory divergence: The FDA and EMA are increasingly diverging on accelerated approval pathways, AI/digital health regulation, and biosimilar interchangeability rules. The EU's regulatory sandbox (new in the 2026 reform) has no US equivalent in the same form
• GMP mutual recognition: The EU-US Mutual Recognition Agreement on GMP inspections (fully operational since 2019) reduces duplicative inspections. This is the most successful transatlantic pharma cooperation mechanism
• China factor: Both the EU and US are seeking to reduce dependency on Chinese API (active pharmaceutical ingredient) manufacturing. The EU's proposed Critical Medicines Act and the US BIOSECURE Act both aim to reshore production
• Drug pricing: The US Inflation Reduction Act (IRA) introduced Medicare drug price negotiation for the first time, narrowing the EU-US price gap for selected medicines. This affects European companies' global pricing strategies